Your browser doesn't support javascript.
loading
Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myeloma.
Awada, Hussein; Hajj Ali, Adel; Ali, Muhammad Faizan; Sauter, Craig; Hamilton, Betty; Kalaycio, Matt; Sobecks, Ronald; Jagadeesh, Deepa; Dean, Robert; Winter, Allison; Pohlman, Brad; Williams, Louis; Anwer, Faiz; Khouri, Jack.
Afiliação
  • Awada H; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Hajj Ali A; Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Ali MF; Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, 44307, USA.
  • Sauter C; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Hamilton B; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Kalaycio M; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Sobecks R; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Jagadeesh D; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Dean R; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Winter A; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Pohlman B; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Williams L; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Anwer F; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
  • Khouri J; Multiple Myeloma Program, Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
Eur J Haematol ; 110(6): 780-783, 2023 06.
Article em En | MEDLINE | ID: mdl-36949569
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos